Warfarin pharmacogenetics: Does more accurate dosing benefit patients?

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 7, 2012, Pages 661-666

  Eby, Charles ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

oral anticoagulant therapy; pharmacogenetics; vitamin K antagonist; warfarin

Indexed keywords

CYTOCHROME P450 2C9; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); WARFARIN;

AFRICAN AMERICAN; ALGORITHM; ARTICLE; ASIAN; BODY SIZE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG SENSITIVITY; EUROPEAN AMERICAN; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WARFARIN;

EID: 84872107328     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1326789     Document Type: Article

References (50)

1. Witt D. M. Approaches to Optimal Dosing of Vitamin K Antagonists. Semin Thromb Hemost: 2012; 38 7 667 672
2. Lindh J. D., Holm L., Dahl M. L., Alfredsson L., Rane A. Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis: 2008; 25 2 151 159
3. Linkins L. A., Choi P. T., Douketis J. D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med: 2003; 139 11 893 900
4. Fihn S. D., McDonell M., Martin D., et al. Warfarin Optimized Outpatient Follow-up Study Group. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med: 1993; 118 7 511 520
5. Lubitz S. A., Scott S. A., Rothlauf E. B., et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost: 2010; 8 5 1018 1026
6. Rettie A. E., Korzekwa K. R., Kunze K. L., et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol: 1992; 5 1 54 59
7. Kaminsky L. S., Zhang Z. Y. Human P450 metabolism of warfarin. Pharmacol Ther: 1997; 73 1 67 74
8. Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet: 2001; 40 8 587 603
9. Lee C. R., Goldstein J. A., Pieper J. A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics: 2002; 12 3 251 263
10. Marsh S., King C. R., Porche-Sorbet R. M., Scott-Horton T. J., Eby C. S. Population variation in VKORC1 haplotype structure. J Thromb Haemost: 2006; 4 2 473 474
11. Cavallari L. H., Langaee T. Y., Momary K. M., et al. Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans. Clin Pharmacol Ther: 2010; 87 459 464
12. Rost S., Fregin A., Ivaskevicius V., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature: 2004; 427 6974 537 541
13. Li T., Chang C. Y., Jin D. Y., Lin P. J., Khvorova A., Stafford D. W. Identification of the gene for vitamin K epoxide reductase. Nature: 2004; 427 6974 541 544
14. Rieder M. J., Reiner A. P., Gage B. F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med: 2005; 352 22 2285 2293
15. Yuan H. Y., Chen J. J., Lee M. T., et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet: 2005; 14 13 1745 1751
16. Voora D., Koboldt D. C., King C. R., et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther: 2010; 87 4 445 451
17. King C. R., Deych E., Milligan P., et al. Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost: 2010; 104 4 750 754
18. Cooper G. M., Johnson J. A., Langaee T. Y., et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood: 2008; 112 4 1022 1027
19. Takeuchi F., McGinnis R., Bourgeois S., et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet: 2009; 5 3 e1000433
20. Teichert M., Eijgelsheim M., Rivadeneira F., et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet: 2009; 18 19 3758 3768
21. Caldwell M. D., Awad T., Johnson J. A., et al. CYP4F2 genetic variant alters required warfarin dose. Blood: 2008; 111 8 4106 4112
22. Liang R., Wang C., Zhao H., Huang J., Hu D., Sun Y. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thromb Res: 2012; 130 1 38 44
23. McDonald M. G., Rieder M. J., Nakano M., Hsia C. K., Rettie A. E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol: 2009; 75 6 1337 1346
24. Perera M. A., Gamazon E., Cavallari L. H., et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther: 2011; 89 3 408 415
25. Moreau C., Bajolle F., Siguret V., et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood: 2012; 119 3 861 867
26. Biss T. T., Avery P. J., Brandão L. R., et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood: 2012; 119 3 868 873
27. Klein T. E., Altman R. B., Eriksson N., et al. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med: 2009; 360 8 753 764
28. Gage B. F., Eby C., Johnson J. A., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther: 2008; 84 3 326 331
29. Anderson J. L., Horne B. D., Stevens S. M., et al. Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation: 2007; 116 22 2563 2570
30. Lenzini P., Wadelius M., Kimmel S., et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther: 2010; 87 5 572 578
31. Horne B. D., Lenzini P. A., Wadelius M., et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost: 2012; 107 2 232 240
32. Finkelman B. S., Gage B. F., Johnson J. A., Brensinger C. M., Kimmel S. E. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol: 2011; 57 5 612 618
33. Epstein R. S., Moyer T. P., Aubert R. E., et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol: 2010; 55 25 2804 2812
34. Millican E. A., Lenzini P. A., Milligan P. E., et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood: 2007; 110 5 1511 1515
35. Lenzini P. A., Grice G. R., Milligan P. E., et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost: 2008; 6 10 1655 1662
36. Burmester J. K., Berg R. L., Yale S. H., et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med: 2011; 13 6 509 518
37. Hillman M. A., Wilke R. A., Yale S. H., et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res: 2005; 3 3 137 145
38. Caraco Y., Blotnick S., Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther: 2008; 83 3 460 470
39. McMillin G. A., Melis R., Wilson A., et al. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Ther Drug Monit: 2010; 32 3 338 345
40. Holbrook A., Schulman S., Witt D. M., et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST: 2012; 141 e152S 84S
41. French B., Joo J., Geller N. L., et al. COAG (Clarification of Optimal Anticoagulation through Genetics) Investigators. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials: 2010; 11 108
42. Do E. J., Lenzini P., Eby C. S., et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J: 2011;. [Epub ahead of print]
43. van Schie R. M., Wadelius M. I., Kamali F., et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics: 2009; 10 10 1687 1695
44. Anderson J. L., Horne B. D., Stevens S. M., et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation: 2012; 125 16 1997 2005
45. Maurice C. B., Barua P. K., Simses D., Smith P., Howe J. G., Stack G. Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping. Clin Chim Acta: 2010; 411 13-14 947 954
46. Langley M. R., Booker J. K., Evans J. P., McLeod H. L., Weck K. E. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn: 2009; 11 3 216 225
47. King C. R., Porche-Sorbet R. M., Gage B. F., et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol: 2008; 129 6 876 883
48. Poe B. L., Haverstick D. M., Landers J. P. Warfarin genotyping in a single PCR reaction for microchip electrophoresis. Clin Chem: 2012; 58 4 725 731
49. Carlquist J. F., Anderson J. L. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation: 2011; 124 23 2554 2559
50. Schulman S., Crowther M. A. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood: 2012; 119 13 3016 3023